Literature DB >> 19277588

Model systems for examining effects of leukemia-associated oncogenes in primary human CD34+ cells via retroviral transduction.

Mark Wunderlich1, James C Mulloy.   

Abstract

The use of primary human cells to model cancer initiation and progression is now within the grasp of investigators. It has been nearly a decade since the first defined genetic elements were introduced into primary human epithelial and fibroblast cells to model oncogenesis. This approach has now been extended to the hematopoietic system, with the first described experimental transformation of primary human hematopoietic cells. Human cell model systems will lead to a better understanding of the species and cell type specific signals necessary for oncogenic initiation and progression, and will allow investigators to interrogate the cancer stem cell hypothesis using a well-defined hierarchical system that has been studied for decades. The molecular and biochemical link between self-renewal and differentiation can now be experimentally approached using primary human cells. In addition, the models that result from these experiments are likely to generate highly relevant systems for use in identification and validation of potential therapeutic targets as well as testing of small molecule therapeutics. We describe here the methodologies and reagents that are used to examine the effects of leukemia fusion protein expression on primary human hematopoietic cells, both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277588      PMCID: PMC2825883          DOI: 10.1007/978-1-59745-418-6_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

1.  SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection.

Authors:  Jianfeng Wang; Takafumi Kimura; Rumiko Asada; Sachio Harada; Shouhei Yokota; Yoshio Kawamoto; Yoshihiro Fujimura; Takashi Tsuji; Susumu Ikehara; Yoshiaki Sonoda
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

2.  Species- and cell type-specific requirements for cellular transformation.

Authors:  Annapoorni Rangarajan; Sue J Hong; Annie Gifford; Robert A Weinberg
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

3.  Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element.

Authors:  James C Mulloy; Jorg Cammenga; Francisco J Berguido; Kaida Wu; Ping Zhou; Raymond L Comenzo; Suresh Jhanwar; Malcolm A S Moore; Stephen D Nimer
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

4.  Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells.

Authors:  D S Pereira; C Dorrell; C Y Ito; O I Gan; B Murdoch; V N Rao; J P Zou; E S Reddy; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

5.  Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow.

Authors:  K Itoh; H Tezuka; H Sakoda; M Konno; K Nagata; T Uchiyama; H Uchino; K J Mori
Journal:  Exp Hematol       Date:  1989-02       Impact factor: 3.084

6.  A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow.

Authors:  Takashi Yahata; Kiyoshi Ando; Tadayuki Sato; Hiroko Miyatake; Yoshihiko Nakamura; Yukari Muguruma; Shunichi Kato; Tomomitsu Hotta
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

7.  Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.

Authors:  M Feuring-Buske; B Gerhard; J Cashman; R K Humphries; C J Eaves; D E Hogge
Journal:  Leukemia       Date:  2003-04       Impact factor: 11.528

8.  Creation of human tumour cells with defined genetic elements.

Authors:  W C Hahn; C M Counter; A S Lundberg; R L Beijersbergen; M W Brooks; R A Weinberg
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

Review 9.  Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice.

Authors:  Annapoorni Rangarajan; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

10.  NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration.

Authors:  F E Nicolini; J D Cashman; D E Hogge; R K Humphries; C J Eaves
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

View more
  11 in total

1.  Deacetylase activity of histone deacetylase 3 is required for productive VDJ recombination and B-cell development.

Authors:  Kristy R Stengel; Kelly R Barnett; Jing Wang; Qi Liu; Emily Hodges; Scott W Hiebert; Srividya Bhaskara
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

2.  Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Authors:  Katelyn Melgar; Morgan M Walker; LaQuita M Jones; Lyndsey C Bolanos; Kathleen Hueneman; Mark Wunderlich; Jian-Kang Jiang; Kelli M Wilson; Xiaohu Zhang; Patrick Sutter; Amy Wang; Xin Xu; Kwangmin Choi; Gregory Tawa; Donald Lorimer; Jan Abendroth; Eric O'Brien; Scott B Hoyt; Ellin Berman; Christopher A Famulare; James C Mulloy; Ross L Levine; John P Perentesis; Craig J Thomas; Daniel T Starczynowski
Journal:  Sci Transl Med       Date:  2019-09-04       Impact factor: 17.956

3.  Definition of a small core transcriptional circuit regulated by AML1-ETO.

Authors:  Kristy R Stengel; Jacob D Ellis; Clare L Spielman; Monica L Bomber; Scott W Hiebert
Journal:  Mol Cell       Date:  2020-12-30       Impact factor: 17.970

4.  Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.

Authors:  S Goyama; M Shrestha; J Schibler; L Rosenfeldt; W Miller; E O'Brien; B Mizukawa; T Kitamura; J S Palumbo; J C Mulloy
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

Review 5.  Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.

Authors:  Susumu Goyama; James C Mulloy
Journal:  Int J Hematol       Date:  2011-05-03       Impact factor: 2.490

6.  In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Authors:  Anmaar M Abdul-Nabi; Enas R Yassin; Nobish Varghese; Hrishikesh Deshmukh; Nabeel R Yaseen
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

7.  UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.

Authors:  S Goyama; J Schibler; A Gasilina; M Shrestha; S Lin; K A Link; J Chen; S P Whitman; C D Bloomfield; D Nicolet; S A Assi; A Ptasinska; O Heidenreich; C Bonifer; T Kitamura; N N Nassar; J C Mulloy
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

8.  Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.

Authors:  Susumu Goyama; Janet Schibler; Lea Cunningham; Yue Zhang; Yalan Rao; Nahoko Nishimoto; Masahiro Nakagawa; Andre Olsson; Mark Wunderlich; Kevin A Link; Benjamin Mizukawa; H Leighton Grimes; Mineo Kurokawa; P Paul Liu; Gang Huang; James C Mulloy
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

9.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Authors:  Johannes Zuber; Junwei Shi; Eric Wang; Amy R Rappaport; Harald Herrmann; Edward A Sison; Daniel Magoon; Jun Qi; Katharina Blatt; Mark Wunderlich; Meredith J Taylor; Christopher Johns; Agustin Chicas; James C Mulloy; Scott C Kogan; Patrick Brown; Peter Valent; James E Bradner; Scott W Lowe; Christopher R Vakoc
Journal:  Nature       Date:  2011-08-03       Impact factor: 49.962

10.  Improved multilineage human hematopoietic reconstitution and function in NSGS mice.

Authors:  Mark Wunderlich; Fu-Sheng Chou; Christina Sexton; Pietro Presicce; Claire A Chougnet; Julio Aliberti; James C Mulloy
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.